Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway.

中文翻译：

---

COVID-19 中的 I 型干扰素反应：对治疗的影响。

尽管有相反的早期报道，但越来越多的证据表明，重症 COVID-19 患者具有强烈的 I 型干扰素反应，这与感染早期出现的延迟、可能被抑制的干扰素反应形成鲜明对比。强大的 I 型干扰素反应可能通过多种机制加剧向严重 COVID-19 发展的过度炎症。进一步了解 I 型干扰素在不同感染阶段以及在轻度和重度 COVID-19 患者中的作用将为 COVID-19 患者中干扰素给药或 JAK 抑制剂的治疗用途提供见解。在这篇评论中，